61.86
-0.17 (-0.27%)
| Previous Close | 62.03 |
| Open | 61.50 |
| Volume | 1,242,517 |
| Avg. Volume (3M) | 1,370,163 |
| Market Cap | 5,501,091,840 |
| Price / Earnings (TTM) | 363.88 |
| Price / Earnings (Forward) | 29.41 |
| Price / Sales | 19.06 |
| Price / Book | 49.94 |
| 52 Weeks Range | |
| Earnings Date | 12 Aug 2026 |
| Operating Margin (TTM) | -1,135.42% |
| Diluted EPS (TTM) | -1.71 |
| Quarterly Revenue Growth (YOY) | 5.00% |
| Total Debt/Equity (MRQ) | 297.04% |
| Current Ratio (MRQ) | 2.93 |
| Operating Cash Flow (TTM) | -99.23 M |
| Levered Free Cash Flow (TTM) | -64.38 M |
| Return on Assets (TTM) | -37.66% |
| Return on Equity (TTM) | -203.98% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Bullish |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Bullish | |
| Stock | Liquidia Corporation | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | -3.0 |
| Insider Activity | -4.0 |
| Price Volatility | -3.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 4.0 |
| Average | -1.70 |
|
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Core |
| % Held by Insiders | 13.64% |
| % Held by Institutions | 65.04% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Findell Capital Management Llc | 31 Mar 2026 | 3,502,112 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 55.00 (HC Wainwright & Co., -11.09%) | Buy |
| Median | 52.00 (-15.94%) | |
| Low | 44.00 (Wells Fargo, -28.87%) | Buy |
| Average | 50.75 (-17.96%) | |
| Total | 4 Buy | |
| Avg. Price @ Call | 35.28 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 06 Mar 2026 | 55.00 (-11.09%) | Buy | 36.03 |
| Wells Fargo | 06 Mar 2026 | 44.00 (-28.87%) | Buy | 36.03 |
| BTIG | 05 Mar 2026 | 50.00 (-19.17%) | Buy | 34.52 |
| Needham | 05 Mar 2026 | 54.00 (-12.71%) | Buy | 34.52 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |